WASHINGTON, D.C. — The U.S. Department of Health and Human Services (HHS) announced March 12 a collaboration with the American Urological Association aimed at increasing awareness and clinician education on treatments for postmenopausal women experiencing genitourinary syndrome of menopause (GSM) and recurrent urinary tract infections.

The agreement, outlined in a memorandum of understanding between HHS’ Office on Women’s Health and the AUA and its affiliated organizations, focuses on promoting the appropriate, evidence-based use of local estrogen therapy.

Health officials say declining estrogen after menopause can lead to changes in urogenital tissue and bacterial balance, increasing the risk of urinary tract infections and related complications. Evidence cited by HHS indicates localized estrogen therapy may help restore tissue health and reduce recurrent infections.

The memorandum takes effect immediately for one year and may be extended by mutual agreement for up to five years. Either organization may end the agreement with 60 days’ written notice.